# Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

> **NCT07502664** · — · RECRUITING · sponsor: **Ray Therapeutics, Inc.** · enrollment: 25 (estimated)

## Conditions studied

- Retinitis Pigmentosa
- Stargardt Macular Dystrophy
- Stargardt Disease
- Geographic Atrophy From Age-related Macular Degeneration
- X-linked Retinoschisis
- Retinal Dystrophies

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07502664
- **Lead sponsor:** Ray Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-19
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502664, "Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07502664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*